{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T19:51:12Z","timestamp":1773777072620,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR2070B"],"award-info":[{"award-number":["SHDC2020CR2070B"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e30123","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T23:20:21Z","timestamp":1713655221000},"page":"e30123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma"],"prefix":"10.1016","volume":"10","author":[{"given":"Jun-Ting","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0726-4635","authenticated-orcid":false,"given":"Yu-Tian","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Le","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Jia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Kun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1148\/radiol.10091809","article-title":"Staging Monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems","volume":"257","author":"Fechtner","year":"2010","journal-title":"Radiology"},{"issue":"26","key":"10.1016\/j.heliyon.2024.e30123_bib4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30123_bib5","unstructured":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report within the HARMONY Project."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30123_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30123_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30123_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e30123_bib9","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"33","key":"10.1016\/j.heliyon.2024.e30123_bib10","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30123_bib11","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e30123_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.010","article-title":"The complexity of p53-mediated metabolic regulation in tumor suppression","volume":"85","author":"Liu","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30123_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020287","article-title":"Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e30123_bib14","first-page":"248","article-title":"Decoding the role of miRNAs in multiple myeloma pathogenesis: a focus on signaling pathways","author":"Yehia","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.heliyon.2024.e30123_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the scene: immune cells in the myeloma niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30123_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000443275","article-title":"The impact of mast cell density on the progression of bone disease in multiple myeloma patients","volume":"168","author":"Vyzoukaki","year":"2015","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30123_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30123_bib18","article-title":"Inappropriate expression of PD-1 and CTLA-4 checkpoints in myeloma patients is more pronounced at diagnosis: implications for time to progression and response to therapeutic checkpoint inhibitors","volume":"24","author":"de Nalecz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30123_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30123_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: a review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30123_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30123_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30123_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.heliyon.2024.e30123_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinf."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30123_bib25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"33","key":"10.1016\/j.heliyon.2024.e30123_bib26","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30123_bib27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/15548627.2019.1635380","article-title":"MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4","volume":"16","author":"Wu","year":"2020","journal-title":"Autophagy"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30123_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108500","article-title":"Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma: a meta-analysis of three large cohorts and functional characterization","volume":"24","author":"Clavero","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30123_bib29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib30","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e30123_bib31","article-title":"Natural killer cells in the malignant niche of multiple myeloma","volume":"12","author":"Venglar","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30123_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-017-0256-z","article-title":"Adoptive cell therapy using PD-1(+) myeloma-reactive T cells eliminates established myeloma in mice","volume":"5","author":"Jing","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4274\/tjh.galenos.2020.2020.0115","article-title":"Evaluation of prognostic significance of the international staging system according to glomerular filtration rate in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation","volume":"38","author":"Ciftciler","year":"2021","journal-title":"Turkish Journal of Hematology"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30123_bib34","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 Regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"Jnci-Journal of the National Cancer Institute"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30123_bib36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30123_bib37","article-title":"Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30123_bib38","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026062","article-title":"Tumor-suppressor functions of the TP53 pathway","volume":"6","author":"Aubrey","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.heliyon.2024.e30123_bib39","first-page":"100","article-title":"Roadmap to cure multiple myeloma","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30123_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17474086.2021.1909469","article-title":"A new decade: novel immunotherapies on the horizon for relapsed\/refractory multiple myeloma","volume":"14","author":"Braunstein","year":"2021","journal-title":"Expet Rev. Hematol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30123_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e30123_bib42","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/bloodadvances.2017011601","article-title":"CD86 regulates myeloma cell survival","volume":"1","author":"Gavile","year":"2017","journal-title":"Blood Advances"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30123_bib43","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/1541-7786.MCR-21-0681","article-title":"PDZ proteins SCRIB and DLG1 regulate myeloma cell surface CD86 expression, growth, and survival","volume":"20","author":"Moser-Katz","year":"2022","journal-title":"Mol. Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024061541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024061541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:52:47Z","timestamp":1773766367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024061541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024061541"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30123","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating p53-associated genes and infiltrating immune cell characterization as a prognostic biomarker in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30123"}}